UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020124
Receipt number R000023247
Scientific Title Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations
Date of disclosure of the study information 2015/12/08
Last modified on 2015/12/08 22:25:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations

Acronym

Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations

Scientific Title

Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations

Scientific Title:Acronym

Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations

Region

Japan


Condition

Condition

Chronic hepatitis B

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of the safety, and efficacy of the preceding administration of Entecavir with PEG-IFN-alfa2a for young patients with chronic hepatitis B

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The ratio of HBV-DNA titer, below 4 log copies/mL after 48 weeks of preceding administration of Entecavir with PEG-IFN-alfa2a

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of Entecavir for at least 24 weeks since the beginning of treatment
At 20 weeks, HBV-DNA titer below 4log, then switch to PEG-IFN-alfa2a
At 20 weeks, HBV-DNA titer more than 4log, Entecavir would be continued
At the onset of HBV-DNA below 4log, switch to PEG-IFN-alfa2a, continued for 48 weeks
The maxim duration of Entecavir would be 48 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

40 years-old >

Gender

Male and Female

Key inclusion criteria

1. Age below 40 years old
2. Patient with chronic hepatitis B, untreated with IFN or nuclear analogue
Non-cirrhosis
3. Genotype C, HBe Antigen positive, HBV-DNA over 7log copies, ALT over 100IU/L
Just before the trial, Neutrophil more than 1,500/ul, Platelet more than 90,000/ul, hemoglobin more than 10g/dl
4. ECOG performance status 0 or 1
5. Obtained an informed consent from all study participants

Key exclusion criteria

1. HCV antibody positive
2. Liver cirrhosis
3. Pregnancy or lactation period
4. Entecavir or interferon therapy before the study
5. Treated with shou-saikotou (Kampo medicine)
6. Past history of interstitial pneumoniae
7. Past history of autoimmune hepatitis
8. Allergy with vaccination
9. Severe mentally disordered, severe psychotic disease
10. Others

Target sample size

26


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Michihiro Suzuki

Organization

St. Marianna University School of Medicine

Division name

Division of Gastroenterology and Hepatology, Department of Internal Medicine

Zip code


Address

2-16-1 Sugao, Miyamae-ku, Kawasaki City, Kanagawa 216-8511, Japan

TEL

044-977-8111

Email

michstmu@marianna-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroki Ikeda

Organization

St. Marianna University School of Medicine

Division name

Division of Gastroenterology and Hepatology, Department of Internal Medicine

Zip code


Address

2-16-1 Sugao, Miyamae-ku, Kawasaki City, Kanagawa 216-8511, Japan

TEL

044-977-8111

Homepage URL


Email

ikedahi@marianna-u.ac.jp


Sponsor or person

Institute

Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine,

Institute

Department

Personal name



Funding Source

Organization

Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine,

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 12 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2014 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2014 Year 03 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 12 Month 08 Day

Last modified on

2015 Year 12 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023247


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name